Two tests and one reference [General Sta­tis­tics]

posted by Brus – Spain, 2020-08-31 11:58 (1412 d 17:04 ago) – Posting: # 21895
Views: 7,148

Dear Helmut and all,

If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?

In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).

If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?

Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?

Best regards,

Complete thread:

UA Flag
Activity
 Admin contact
23,099 posts in 4,857 threads, 1,646 registered users;
66 visitors (0 registered, 66 guests [including 8 identified bots]).
Forum time: 05:03 CEST (Europe/Vienna)

Genius is one per cent inspiration and ninety-nine per cent perspiration.
Accordingly, a ‘genius’ is often merely a talented person
who has done all of his or her homework.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5